-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Meeting News
-
Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation
The referenced media source is missing and needs to be re-embedded.
-
TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse
By Kara Nyberg, PhD Posted: June 24, 2020 New findings from the TRACERx lung study underscore the value of using circulating tumor DNA (ctDNA) to predict NSCLC relapse postsurgery based on the detection of minimal residual disease (MRD). Moreover, the results appear sufficiently robust to begin to support use of ctDNA as a biomarker for…
-
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
By Kara Nyberg, PhD Posted: June 24, 2020 An exploratory analysis of circulating free DNA (cfDNA) shows that lorlatinib confers potent antitumor activity in pretreated patients with ALK-positive NSCLC regardless of EML4-ALK variant type and across a variety of ALK resistance mutations. The duration of response also appears consistent across all ALK fusion subtypes. “Our…
-
PASSION Results Support Further Study of Camrelizumab Plus Apatinib in SCLC
By Kara Nyberg, PhD Posted: June 24, 2020 The phase II PASSION trial sought to explore the potential synergy between immunotherapy and antiangiogenic drug therapy previously observed in preclinical studies. As reported at AACR, the trial showed that combined second-line treatment with camrelizumab, a PD-1 inhibitor, and apatinib, a VEGFR2 inhibitor, demonstrated promising antitumor activity…
-
Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune Checkpoint Inhibitor Therapy
By Kara Nyberg, PhD Posted: June 24, 2020 Pneumonitis is a well-known complication associated with immune checkpoint inhibitors (ICI). A collaborative effort between the U.S. Food and Drug Administration (FDA) and Synapse, a consultancy firm, retrospectively analyzed both clinical trial data and real-world data (RWD) taken from the Advocate Aurora Health System to elucidate risk…
-
Single-Agent Pembrolizumab Active Against STK11- and KEAP1- Mutated NSCLC According to KEYNOTE-042 Analysis
By Kara Nyberg, PhD Posted: June 24, 2020 Genomic alterations in STK11 and KEAP1 represent two of the most common and potent contributors to a cold tumor immune microenvironment in nonsquamous NSCLC. Although prior research has shown that these mutations are tied to poor outcomes in patients treated with immune checkpoint blockade, particularly in the…
-
Impact of COVID-19 on the Diagnostic Workup of Lung Cancer
The COVID-19 pandemic has created numerous challenges with the management of lung cancer, not the least of which is the initial diagnosis. The computer tomography scans, typically used in the diagnostic workup, can be obfuscated by the COVID-19 radiologic features therefore this webinar will discuss the best practices on how to distinguish the two. Bronchoscopic…
-
Systemic Therapy for Advanced Stage Lung Cancer During the COVID-19 Pandemic
Watch Recording IASLC faculty members from Europe, Asia and North America will discuss systemic therapies including chemotherapy, immunotherapy, and targeted therapy for advanced-stage lung cancer during the COVID-19 global pandemic. The faculty will share their experience and advice on 1) how COVID-19 impacts their patient population, 2) changes made in the management of current and…
-
Impact of COVID-19 on Treatment of Lung Cancer Patients with Local or Locoregional Disease
Watch Recording This webinar, “Impact of COVID-19 on Treatment of Lung Cancer Patients with Local or Locoregional Disease,” will be presented by IASLC surgical and radiation oncology experts. Faculty will address topics such as postponing surgery and/or radiation depending on the patient’s SARS-CoV-2 status; post-surgery discharge time; operating suite preparation for a SARS-CoV-2 positive patient;…
-
Practical Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement
This webinar will give a summary of recently published ESTRO & ASTRO practice guidelines about radiotherapy for lung cancer in the COVID-19 pandemic, whether radiotherapy can or should be adapted, and if so how should this be done. We will address questions about whether radiotherapy can be delayed, fractionation of radiotherapy, multimodality treatment strategies and handling…